Clinical trials: Depression NOS
Treatment Resistant Depression
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Randomized, two-part, placebo-controlled study of single ascending doses of NV-5138 in healthy volunteers, and a single dose of NV-5138 in subjects with Treatment-Resistant Depression (TRD)
- Trial name
- NCT03606395
- Testing
- NV-5138
- Where
- 9 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Navitor Pharmaceuticals, Inc.
Panic Disorder, Depression
Drug Use Investigation of Jzoloft.
The objective of this surveillance is to collect information about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00605865
- Testing
- Sertraline hydrochloride
- Volunteers
- 2,272 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatment Resistant Depression
Virtual Neuro-Navigation System for Personalized Community Based TMS
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
- Trial name
- NCT04956081
- Testing
- Neuro-navigated Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Soterix Medical
Depression
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
- Trial name
- NCT07485595
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Depression, Bipolar
Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the…
- Trial name
- NCT00191399
- Testing
- Olanzapine, Fluoxetine
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Mild Cognitive Impairment, Anxiety State
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
This Phase I/II clinical trial aims to test the effectiveness of a new sublingual formulation of 5-MeO-DMT in reducing symptoms of anxiety, depression, and cognitive decline in individuals with mild to moderate Alzheimer's…
- Conditions
- Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder
- Trial name
- 5-MeO-DMT (NCT06812221)
- Testing
- Sublingual administration, Electroencephalography, Biochemical mesurements
- Where
- Argentina
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biomind Labs Inc.
Treatment Resistant Depression
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve…
- Trial name
- RESTORE-LIFE (NCT03320304)
- Testing
- Vagal Nerve Simulation (VNS) Therapy
- Where
- 18 sites in Austria, Belgium and 2 more
- Volunteers
- 500 people
- Sponsor
- LivaNova
Bipolar Depression, Suicidal Ideation
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of…
- Trial name
- SBD-ASIB (NCT03396068)
- Testing
- NRX-101, Lurasidone HCl
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838876
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Multiple Sclerosis
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis
Fampyra, a voltage-dependent potassium channel blocker, is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
- Trial name
- FAMILY (NCT03164018)
- Testing
- Fampridine
- Where
- Greece
- Volunteers
- 111 people
- Sponsor
- Genesis Pharma CNS & Specialty
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.
Major Depressive Disorder
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety and tolerability of agomelatine 25 mg or 50 mg per day and will compare agomelatine and paroxetine tolerability.
- Trial name
- NCT00463242
- Testing
- Agomelatine, paroxetine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 501 people
- Sponsor
- Novartis
Major Depressive Disorder (MDD)
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo.
- Trial name
- Tarian-1 (NCT07300969)
- Testing
- DT-101
- Where
- 43 sites in United States, Bulgaria and 3 more
- Volunteers
- 300 people
- Sponsor
- Draig Therapeutics Ltd
Diabetes, Hypertension
Quality IQ Patient Simulation Physician Practice Measurement and Engagement
This study will test the quality of physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback.
- Conditions
- Diabetes, Hypertension, Depression, Osteoarthritis
- Trial name
- Q-IQ (NCT03800901)
- Testing
- Continuing Medical Education, Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Depression, Teen
Digital Therapeutic vs Psychoeducation for Management of Mild to Moderate Depression in Adolescents
The purpose of the present randomized controlled study is to investigate if there is a difference in depression symptoms at 4-weeks among adolescents ages 16-17 years assigned to W-GenZD, a digital therapeutic, as compared to a…
- Trial name
- NCT04985331
- Testing
- W-GenZD
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Woebot Health
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01163266
- Testing
- Vortioxetine
- Where
- 39 sites in United States
- Volunteers
- 462 people
- Sponsor
- Takeda
Depression
A Mobile and Virtual Reality Intervention for Adolescent Depression
Depression, the most common mental health disorder among adolescents, is a critical health problem within the US. In this study, the feasibility, acceptability, and preliminary efficacy of Limbix Spark, a cognitive behavioral…
- Trial name
- NCT04165681
- Testing
- Limbix Spark
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Limbix Health, Inc.
Major Depressive Disorder (MDD
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
The purpose of this study is to learn about: To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or…
- Trial name
- NCT07193901
- Testing
- Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray
- Where
- 15 sites in China
- Volunteers
- 98 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Anxiety, Self-Efficacy
Musically-Guided Paced Breathing Improves Mental Health in War-Affected Adolescents
Examine the impact of a mindfulness condition, a guided paced breathing audiovisual intervention condition, and a guided paced breathing audiovisual intervention plus take-home application condition compared to a matched control…
- Conditions
- Anxiety, Self-Efficacy, Depression Not Otherwise Specified
- Trial name
- NCT06988800
- Testing
- Paced breathing wellness breathing sessions, Mindfulness video sessions
- Where
- Palestinian Territories
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Muvik Labs